Background {#Sec1}
==========

Pancreatic adenocarcinoma is the fourth leading cause of cancer death in the United States with a dismal 5 year survival of 8% \[[@CR1]\]. Surgical resection remains the only potential curative approach in the treatment of this disease, though only 20% of patients are initially able to undergo resection \[[@CR2]\]. For patients with unresectable pancreatic cancer, induction chemotherapy (iC), concurrent chemoradiation (CRT) and radiation therapy (RT) alone are among the combination of regimens that have been used as various treatment options.

The role of RT in the setting of locally advanced pancreatic cancer is controversial since responses are limited and the predominant cause of death in these patients is distant metastatic disease. More recent evidence from postmortem studies has shown that up to 30% of deaths from pancreatic cancer are due to locally advancing disease, pointing to the importance of local control in preventing tumor progression and potentially improving overall survival \[[@CR3]\].

Radiation dose escalation has been posited as a potential strategy to improve outcomes in this challenging patient population, though results have been mixed. A phase II study of RT alone found that dose escalation to 70--72 Gy was feasible \[[@CR4]\]. A National Cancer Database (NCDB) review of patients who received definitive CRT for unresectable pancreatic cancer did not find an overall survival (OS) benefit with the use of RT doses exceeding 45 Gy \[[@CR5]\]. Institutional reports have found that dose escalation may provide a significant survival benefit when used in conjunction with iC \[[@CR6]--[@CR8]\].

This study used the NCDB to identify patients with non-metastatic, unresected pancreatic cancer in order to evaluate the role of dose-escalated CRT. We further sought to compare the outcomes of dose escalation in those patients who received iC prior to CRT versus those who underwent definitive CRT alone.

Methods {#Sec2}
=======

Patient population {#Sec3}
------------------

The NCDB registry was used to identify pancreatic adenocarcinoma cases diagnosed between 2004 and 2015 (the most recent dataset available at the time of this study). The NCDB is a national cancer database capturing approximately 70% of cancer incidences in the United States and obtains data from over 1500 hospitals \[[@CR9]\]. It is a de-identified dataset and this study was exempt from institutional review board review.

Our patient selection flow diagram is shown in Fig. [1](#Fig1){ref-type="fig"}. Our initial query identified patients with unresected stage III, clinical T4 N0--1 M0 pancreatic adenocarcinoma who had been treated with curative-intent CRT with or without iC. American Joint Committee on Cancer (AJCC) 6th and 7th editions were used to determine stage III disease in 2004--2015.Fig. 1CONSORT diagram for patient selection criteria. iC: induction chemotherapy; CRT: chemoradiation

To address variability in dose fractionation among hospitals for LAPC, conventionally fractionated radiation therapy (CFRT) was categorized as 1.8--2.5 Gy/fractions up to a total of 45--70 Gy \[[@CR6]\]. The radiation dose was stratified by \< 55 Gy and ≥ 55 Gy based on National Comprehensive Cancer Network (NCCN) guidelines suggesting 45--54 Gy as the standard dose of radiation therapy \[[@CR10]\]. Chemotherapy or radiation therapy delivered within 30 days of each other was considered as CRT. Chemotherapy administered within 31--180 days prior to the radiation therapy was considered as iC followed by CRT. Patients who received chemotherapy more than 180 days prior to radiation therapy were excluded from our analysis. Other exclusion criteria were: having undergone surgery, incomplete follow-up, incomplete radiation dose or fractionation, missing data on the number of days between diagnosis and treatments, and palliative-intent treatments. Those who survived less than 3 months after their diagnosis were excluded in order to omit patients who expired prior to completing their treatment course.

Baseline characteristics for analysis included: treatment facility type, age, gender, race, insurance status, household income, residential setting, Charlson-Deyo Score (CDS), year of diagnosis, the location of primary tumor within the pancreas, tumor size, clinical N stage, single- vs multi-agent chemotherapy (defined by the NCDB as the first course of therapy), radiation dose, and radiation fractionation. Cohorts iC + CRT and CRT were constructed to include patients with and without iC, respectively. Age and tumor size were stratified by ≥65 years or \< 65 years and \< 3.8 cm or ≥ 3.8 cm based on their median values. The household income level of residential area was based on the 2012 American Community Survey data adjusted for inflation (the most recent data at the time of this study), and it was stratified by above or below the median value of \$48,000.

Pertinent prognostic factors such as a patient's performance status, or the type and duration of chemotherapy received are unavailable in the NCDB. Other important outcomes such as toxicity, local and distant recurrences are also unavailable in the NCDB. CA 19--9 factor and tumor grade were missing in 1090 (53.7%) and 1574 (77.6%) patients, respectively. Radiation techniques data for intensity-modulated radiation therapy (IMRT) or conformal 3-D therapy were only available in 457 (61.9%) patients for cohort iC + CRT and 570 (44.2%) patients for cohort CRT. The primary outcome was overall survival (OS), which was characterized as time between the diagnosis and the last follow-up or death.

Statistical analysis {#Sec4}
--------------------

Kaplan-Meier and log-rank tests were used to evaluate OS. Categorical and continuous variables between the \< 55 Gy and ≥ 55 Gy groups were compared using Fisher's exact and Mann-Whitney U tests, respectively. Logistic regression univariable (UVA) and multivariable analyses (MVA) were performed to identify potential predictors for the dose escalation and were reported as odds ratio (OR). Cox proportional hazard UVA and MVA were performed to identify potential predictors for the OS and were reported as hazards ratio (HR). All statistically significant factors from UVA were used to construct the MVA model, which was finalized using a backward stepwise elimination. Potential treatment interactions with other variables were evaluated using Cox MVA by adding interaction terms. To minimize selection bias, propensity score matching was performed. Matching was based on baseline characteristics, including facility type, age, CDS, year of diagnosis, tumor size, clinical N stage, and single- vs multi-agent chemotherapy. Additional variables were included if they were statistically significant in Cox MVA for OS. All matching was performed in a 2:1 ratio without any replacement, using nearest neighbor method with a caliper distance of 0.2 of the standard deviation of the logit of the propensity score \[[@CR11]\]. MatchIt package (version 3.0.1) was used for matching. After matching, matched-sample Cox UVA was used to assess the effect of dose escalation on OS. R software (version 3.4.3, R Foundation for Statistical Computing, Vienna, Austria) was used to perform all aforementioned analyses. All *p* values were two-sided, and the p values less than 0.05 were deemed statistically significant.

Results {#Sec5}
=======

Cohort iC + CRT {#Sec6}
---------------

A total of 2029 patients with unresected clinical stage III T4 N0--1 M0 pancreatic adenocarcinoma treated with concurrent chemoradiation were examined. Of those, 738 patients received iC and were included in cohort iC + CRT. Radiation dose of \< 55 Gy was delivered to 601 patients, while that of ≥55 Gy was given to 137 patients. The majority of patients in this cohort had clinical T4N0M0 adenocarcinoma of the pancreatic head (Table [1](#Tab1){ref-type="table"}). The patient group treated with ≥55 Gy was more likely to have female patients and fewer patients treated in 2012--2015. Other variables were well balanced.Table 1Baseline characteristics, before matchingCohort iC + CRTCohort CRT45--55 Gy55+ Gy45--55 Gy55+ GyN%N%PN%N%PFacility0.390.0031 Nonacademic3355671526726316372 Academic259436547390375826 NA71114042Age10.0081 \< 653035069504744412254 ≥ 652985068505925610346 NA00000000Gender0.0471 Female2974981595144810948 Male3045156415525211652 NA00000000Race0.880.18 White49382115848698219084 Black81131712168162712 Other1933220273 NA81219110Insurance0.310.095 None1222128373 Nonprivate3205363466335911752 Private265447051391379944 NA412114121Income10.45 Above median3896590665465111852 Below median207344734503479743 NA5100172104Residential setting0.330.077 Metro48881114838077615167 Urban77131612189185324 Rural1025434373 NA26421363146Charlson-Deyo Score10.25 0--1575961319610069421796 ≥ 22646460684 NA00000000Year of diagnosis0.016\< 0.001 2004--200752975317309241 2008--20112454174545295010547 2012--2015304515641220212812 NA00000000Primary tumor site0.0680.014 Head4116894697647214062 Body171284331271257433 Tail19300313115 NA00000000Tumor size (cm)0.700.018 \< 3.8265446547486468236 ≥ 3.82834764474484211149 NA53986132123214Clinical N stage0.440.70 03676189656926514364 1234394835374358236 NA00000000Chemotherapy0.200.74 Single agent1662830227897416473 Multi agent4357210778277266127 NA00000000Total radiation dose (Gy)\< 0.001\< 0.001 Median50.459.450.459.4 IQR50.4--52.556.0--59.450.4--52.057.5--60.0Fraction\< 0.001\< 0.001 Median28302832 IQR27--2828--3326--2830--33*iC* induction chemotherapy, *CRT* chemoradiation, *IQR* interquartile range, *NA* not available

On logistic regression UVA, male patients were less likely to receive ≥55 Gy (OR 0.68, *p* = 0.041). No other variables were statistically significant for the receipt of dose escalation.

On Cox MVA (Table [2](#Tab2){ref-type="table"}), having treatments at academic facilities (HR 0.79, *p* = 0.0045), diagnosis between the years 2012--2015 (HR 0.71, *p* = 0.021), the use of multi-agent chemotherapy (HR 0.77, *p* = 0.0041), and dose escalation ≥55 Gy (HR 0.77, *p* = 0.013) were associated with improved survival. After Cox MVA, there was no treatment interaction with age ≥ 65 vs \< 65 (*p* = 0.54), CDS ≥2 vs 0--1 (*p* = 0.90), year of diagnosis (2008--2011, *p* = 0.93, 2012--2015, *p* = 0.89), tumor size ≥3.8 cm vs \< 3.8 cm (*p* = 0.37), or pancreatic tumor site (body and tail, *p* = 0.18). The ideal period of induction chemotherapy was identified using a restricted cubic spline method, which demonstrated HR 1.0 crossing at approximately 91 days. Therefore, two patient population groups were constructed (*n* = 360 for \< 90 days, *n* = 378 for ≥90 days). Longer duration of induction chemotherapy remained statistically significant for improved overall survival in multivariable analysis (HR 0.83, *p* = 0.025).Table 2Cox UVA and MVA for cohort iC + CRTVariableCox UVACox MVAHR95% CIPHR95% CIPFacility Nonacademic1Ref1Ref Academic0.760.65--0.89\< 0.0010.790.67--0.930.0045Age \< 651Ref ≥ 651.040.89--1.210.64Gender Female1Ref1Ref Male1.191.02--1.390.0311.090.93--1.290.29Race White1Ref Black0.860.68--1.100.23 Other0.860.54--1.360.52Insurance None1Ref Nonprivate1.070.57--2.020.82 Private1.070.57--2.010.83Income Above median1Ref Below median1.050.90--1.240.52Residential setting Metro1Ref Urban1.000.79--1.260.98 Rural1.350.80--2.250.26Charlson-Deyo Score 0--11Ref ≥ 21.080.75--1.570.67Year of diagnosis 2004--20071Ref1Ref 2008--20110.950.71--1.280.75 2012--20150.670.50--0.890.00680.710.53--0.950.021Primary tumor site Head1Ref Body0.870.73--1.040.12 Tail1.250.78--2.010.35Tumor size (cm) \< 3.81Ref1Ref ≥ 3.81.201.02--1.410.0271.160.98--1.370.082Clinical N stage 01Ref 11.150.98--1.340.091Chemotherapy Single agent1Ref1Ref Multi agent0.690.58--0.82\< 0.0010.770.64--0.920.0041Dose escalation \< 55 Gy1Ref1Ref ≥ 55 Gy0.800.65--0.970.0270.770.63--0.950.013*UVA* univariate analysis, *MVA* multivariable analysis, *HR* hazard ratio, *CI* confidence interval, *Ref* reference

The overall median follow-up in cohort iC + CRT was 24.3 months (interquartile range \[IQR\] 16.2--38.0). The \< 55 Gy group had a median follow-up of 22.8 months (IQR 15.5--33.6) and the ≥55 Gy group had that of 29.6 months (IQR 22.0--54.2). The median OS was 15.9 months (IQR 11.1--22.4) for the \< 55 Gy group and 16.4 months (IQR 12.0--26.5) for the ≥55 Gy group (log-rank *p* = 0.026). OS at 2 years was 25.1% for the \< 55 Gy group and 35.2% for the ≥55 Gy group.

A total of 387 patients were matched, with 258 patients in the \< 55 Gy group and 129 patients in the ≥55 Gy group. All variables were well balanced between these groups (Table [3](#Tab3){ref-type="table"}). The overall median follow-up for the matched patients was 24.8 months (IQR 16.5--42.7). The median OS was 15.2 months (IQR 10.4--22.3) for the \< 55 Gy group and 16.2 months (IQR 12.0--25.3) for the ≥55 Gy group (log-rank *p* = 0.022). OS at 2 years was 25.4% for the \< 55 Gy group and 33.4% for the ≥55 Gy group (Fig. [2](#Fig2){ref-type="fig"}).Table 3Baseline characteristics, after matchingCohort iC + CRTCohort CRT45--55 Gy55+ Gy45--55 Gy55+ GyN%N%PN%N%PFacility10.26 Nonacademic1295065502737512870 Academic12950645093255530Age0.910.59 \< 65128506550196549351 ≥ 65130506450170469049Charlson-Deyo Score0.650.48 0--124294123953519617897 ≥ 21666515453Income0.65 Above median2055610758 Below median161447642Year of diagnosis0.710.85 2004--200710454133367139 2008--2011131517155177488647 2012--201511745534156152614Tumor size (cm)0.670.78 \< 3.8137536550161447843 ≥ 3.81214764502055610557Clinical N stage0.580.51 01606284652246111864 198384535142396536Chemotherapy0.590.54 Single agent491928222737513272 Multi agent209811017893255128*iC* induction chemotherapy, *CRT* chemoradiationFig. 2Overall survival for cohort iC + CRT, after matching

Cohort CRT {#Sec7}
----------

A total of 1291 patients received no iC and were included in cohort CRT. A radiation dose of \< 55 Gy was delivered to 1066 patients, while that of ≥55 Gy was given to 225 patients. Similar to the cohort one, the majority of patients had clinical T4N0M0 adenocarcinoma of the pancreatic head (Table [1](#Tab1){ref-type="table"}). The ≥55 Gy group was more likely to have patients treated at nonacademic facilities, age \< 65, diagnosis between 2004 and 2007, body of pancreas as a primary site, and larger tumors.

On logistic MVA, patients with treatments at academic facilities (OR 0.65, *p* = 0.015) and a diagnosis between 2012 and 2015 (OR 0.49, *p* = 0.0037) were less likely to receive ≥55 Gy. In contrast, a larger tumor (OR 1.52, *p* = 0.010) was associated with the receipt of ≥55 Gy.

On Cox MVA (Table [4](#Tab4){ref-type="table"}), age ≥ 65 (HR 1.18, *p* = 0.0055) and lower income (HR 1.21, *p* \< 0.001) were associated with higher mortality. In contrast, the use of multi-agent chemotherapy was associated with improved survival (HR 0.81, *p* = 0.0016). On Cox UVA, the association between dose escalation and survival was not statistically significant (HR 0.91, *p* = 0.19) and was excluded from the Cox MVA model. After Cox MVA, no treatment interaction was observed with age ≥ 65 vs \< 65 (*p* = 0.27), CDS ≥2 vs 0--1 (*p* = 0.93), year of diagnosis (2008--2011, *p* = 0.99; 2012--2015, *p* = 0.73), tumor size ≥3.8 cm vs \< 3.8 cm (*p* = 0.75), or pancreatic tumor site (body and tail, *p* = 0.74).Table 4Cox UVA and MVA for cohort CRTVariableCox UVACox MVAHR95% CIPHR95% CIPFacility Nonacademic1Ref1Ref Academic0.890.79--0.9970.0450.910.81--1.030.14Age \< 651Ref1Ref ≥ 651.181.06--1.320.00381.181.05--1.320.0055Gender Female1Ref Male1.050.94--1.170.44Race White1Ref Black0.990.85--1.160.91 Other0.990.67--1.480.98Insurance None1Ref Nonprivate1.330.94--1.880.11 Private1.090.77--1.550.63Income Above median1Ref1Ref Below median1.211.08--1.36\< 0.0011.211.08--1.36\< 0.001Residential setting Metro1Ref Urban1.020.88--1.170.83 Rural1.140.83--1.560.43Charlson-Deyo Score 0--11Ref ≥ 21.010.78--1.300.94Year of diagnosis 2004--20071Ref 2008--20110.920.81--1.040.19 2012--20150.910.77--1.070.25Primary tumor site Head1Ref Body0.960.85--1.090.57 Tail1.040.76--1.430.80Tumor size (cm) \< 3.81Ref ≥ 3.81.080.96--1.210.22Clinical N stage 01Ref 11.090.97--1.220.17Chemotherapy Single agent1Ref1Ref Multi agent0.790.70--0.90\< 0.0010.810.71--0.920.0016Dose escalation \< 55 Gy1Ref ≥ 55 Gy0.910.78--1.050.19*UVA* univariate analysis, *MVA* multivariable analysis, *HR* hazard ratio, *CI* confidence interval, *Ref* reference

The overall median follow-up was 24.6 months (IQR 9.8--51.4) in cohort CRT. The median follow-up was 22.5 months (IQR 8.5--47.6) for the \< 55 Gy group and 30.8 months (IQR 22.6--68.1) for the ≥55 Gy group. The median OS of the \< 55 Gy group was 10.8 months (IQR 7.1--16.9) and that of the ≥55 Gy group was 11.6 months (IQR 7.6--18.1, log-rank *p* = 0.18). OS at 2 years was 11.3% for the \< 55 Gy group and 13.7% for the ≥55 Gy group.

A total of 549 patients were matched, with 366 patients in the \< 55 Gy group and 183 patients in the ≥55 Gy group. All variables were well balanced (Table [3](#Tab3){ref-type="table"}). The overall follow-up for the matched patients was 27.9 months (IQR 11.2--55.2). The median OS of the \< 55 Gy group was 10.6 months (IQR 6.8--16.7) and that of the ≥55 Gy group was 11.8 months (IQR 7.7--18.3, log-rank *p* = 0.16). OS at 2 years was 10.1% for the \< 55 Gy group and 13.3% for the ≥55 Gy group (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Overall survival for cohort CRT, after matching

Total cohort {#Sec8}
------------

3D conformal radiation therapy (3D-CRT) was delivered to 269 patients (*n* = 192 without induction chemotherapy, *n* = 77 with induction chemotherapy) and intensity-modulated radiation therapy (IMRT) was delivered to 690 patients (*n* = 378 without induction chemotherapy, *n* = 312 with induction chemotherapy). For all patients, 3D-CRT was not associated with worse mortality (HR 1.05, 95% CI 0.91--1.22, *p* = 0.50) compared to IMRT. Table [5](#Tab5){ref-type="table"} shows COX UVA/MVA for the total cohort and demonstrates iC improves OS (HR 0.73, *p* \< 0.001) in the multivariable analysis.Table 5Cox UVA and MVA for the total cohortVariableCox UVACox MVAHR95% CIPHR95% CIPFacility Nonacademic1Ref1Ref Academic0.800.73--0.88\< 0.0010.900.81--0.990.036Age \< 651Ref1Ref ≥ 651.151.05--1.260.00271.181.07--1.300.0013Gender Female1Ref1Ref Male1.111.01--1.220.0241.080.98--1.190.13Race White1Ref Black0.960.85--1.100.58 Other0.890.66--1.200.43Insurance None1Ref Nonprivate1.200.88--1.620.25Private1.020.75--1.380.91Income Above median1Ref1Ref Below median1.221.11--1.34\< 0.0011.201.08--1.32\< 0.001Residential setting Metro1Ref Urban1.070.95--1.210.27 Rural1.250.96--1.640.10Charlson-Deyo Score 0--11Ref ≥ 21.060.86--1.300.61Year of diagnosis 2004--20071Ref1Ref 2008--20110.850.76--0.950.00450.920.81--1.050.20 2012--20150.620.55--0.71\< 0.0010.770.66--0.89\< 0.001Primary tumor site Head1Ref Body0.920.83--1.010.088 Tail1.130.87--1.480.35Tumor size (cm) \< 3.81Ref1Ref ≥ 3.81.111.01--1.220.0351.151.04--1.270.0049Clinical N stage 01Ref 11.080.99--1.190.098Chemotherapy Single agent1Ref1Ref Multi agent0.630.57--0.69\< 0.0010.780.69--0.87\< 0.001Induction chemotherapy No1Ref1Ref Yes0.580.53--0.64\< 0.0010.730.65--0.83\< 0.001Dose escalation \< 55 Gy1Ref1Ref ≥ 55 Gy0.860.76--0.970.0120.870.76--0.990.029*UVA* univariate analysis, *MVA* multivariable analysis, *HR* hazard ratio, *CI* confidence interval, *Ref* reference

Discussion {#Sec9}
==========

This NCDB analysis sought to examine the effect of radiation dose escalation in patients with locally advanced pancreatic cancer when given concurrently with chemotherapy. To our knowledge, this is the first study that compares the effect of dose escalation in patients who have received iC versus those who received CRT alone. We show that there is a significant OS benefit with the use of dose-escalated RT with concurrent chemotherapy in patients who have first received iC versus those who receive dose-escalated radiation with concurrent chemotherapy alone.

The use of CRT in the setting of unresectable pancreatic cancer is still controversial. The landmark LAP-07 trial, which randomized patients to CRT compared to chemotherapy alone did not demonstrate an improvement in survival, calling into question the utility of RT in locally advanced pancreatic cancer \[[@CR12]\]. However, this trial was criticized for its randomization of a heterogeneous cohort of patients, as well as for its use of obsolete chemotherapeutic regimens, and historical radiation techniques. Retrospective studies have reported a survival benefit for patients receiving multi-agent induction chemotherapy followed by CRT \[[@CR13]--[@CR15]\]. A recent NCDB analysis similarly showed that maximal systemic chemotherapy prior to CRT improved survival in patients with unresectable, non-metastatic pancreatic cancer \[[@CR16]\]. Interestingly, the Johns Hopkins experience indicated that patients receiving \> 2 cycles of iC had decreased progression and trended toward better OS \[[@CR15]\]. A recent NCDB analysis similarly showed that maximal systemic chemotherapy prior to CRT improved survival in patients with unresectable, non-metastatic pancreatic cancer, which is consistent with our analysis \[[@CR16]\]. Our study adds that in the setting of the maximal systemic chemotherapy prior to CRT, an improved local control with dose-escalated CRT may be translated to an improved OS.

Optimization of the sequencing of chemotherapy and CRT has been explored and is also controversial. A recent investigation by Chung et al. showed a survival advantage in patients receiving a total RT dose ≥61 Gy with concurrent chemotherapy followed by maintenance chemotherapy \[[@CR7]\]. However, the FFCD/SFRO (Fédération Francophone de Cancérologie Digestive/Société Francophone de Radiothérapie Oncologique) phase III trial compared induction chemoradiation to chemotherapy alone, followed by maintenance chemotherapy for all patients with locally advanced, unresectable pancreatic cancer \[[@CR17]\]. They showed that patients receiving the more intensive induction chemoradiation had worse survival than those receiving chemotherapy alone \[[@CR17]\]. This result was corroborated by the Johns Hopkins experience indicating that induction chemotherapy may sensitize tumors to subsequent chemoradiation \[[@CR15]\]. It may also be hypothesized from these data that upfront chemotherapy can affect early micrometastatic disease, allowing for increased efficacy of---and improved overall outcomes with---subsequent local therapy.

Based on the FFCD/SFRO study and the Johns Hopkins experience, our finding that patients who underwent iC had a significant survival benefit with dose escalated RT when compared to those who received CRT alone may be explained by the reduction in distant failures with the use of induction chemotherapy \[[@CR15], [@CR17]\]. Better local control may then translate into improved OS. Just as in the positive retrospective studies of multi-agent chemotherapy, so too did we find on Cox MVA that multi-agent chemotherapy was associated with improved survival in both cohorts \[[@CR13], [@CR14], [@CR16]\]. Since distant failure remains a significant concern in this patient population, any local control benefit that dose escalation may have provided could have been negated in the cohort of patients that did not receive iC. This may explain why dose escalation was ineffective in the absence of iC, but it was effective when used along with iC in prior studies \[[@CR5], [@CR6]\]. This hypothesis cannot be validated in our study since the NCDB does not include data on local or distant failure rates, though it is notable that both cohorts included approximately two-thirds of patients with clinical node-negative (N0) disease, suggesting the presence of micro-metastatic disease may be effectively treated by iC. Of course, this does not account for the presumption that patients who received iC were better performers and were able to receive more aggressive therapy.

The SCALOP-2 (Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer-2) trial is currently enrolling patients with locally advanced, non-metastatic pancreatic cancer on a multi-center, randomized trial evaluating iC followed by standard-dose or dose-escalated radiotherapy with concurrent chemotherapy ([ClinicalTrials.gov](http://clinicaltrials.gov) Number NCT02024009). The results of this study will provide valuable information regarding the benefits and risks associated with intensified local therapies.

Our logistic MVA showed larger tumors were more likely treated with dose-escalated CRT, while treatments in an academic facility were less likely to involve dose escalation. These associations are consistent with a prior NCDB study \[[@CR5]\]. Our Cox MVA showed treatments at academic facilities and recently diagnosed patients in 2012--2015 were associated with improved survival, whereas elderly age was associated with worse mortality. These are consistent with previous studies, and treatments at academic facilities with survival benefits may be due to treatment volume \[[@CR6], [@CR18], [@CR19]\]. Recent diagnosis with improved survival outcomes in our cohort iC + CRT may be due to the recent adoption of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) as iC after the publication of the phase III trial by Conroy et al. in 2011 \[[@CR18], [@CR20]\].

A number of limitations, inherent to any retrospective review, are present in this study. Lack of information regarding chemotherapy regimens prevents a more nuanced stratification of patients. Further, data regarding radiation techniques (3D-CRT or IMRT) was limited in many patients. Nonetheless, we included a comparison of 3D-CRT and IMRT, which showed there was no detriment in survival for the delivery of 3D-CRT. This is important, since recent evaluations have shown superior dosimetric constraints and decreased patient morbidity with the use of IMRT, suggesting that there may be an improvement in outcomes with the use of more conformal RT techniques. However our findings are not consistent with a survival advantage, which may be a result of confounding factors within the group of patients whose radiation technique was coded as "unknown" \[[@CR21]--[@CR23]\]. Performance status is not recorded by the NCDB and was therefore unable to be accounted for in this study. Performance status has been shown to be a prognostic factor for overall survival in patients with pancreatic cancer \[[@CR24]\], though various studies have also reported that its prognostic significance may be lost in multi-variate analysis \[[@CR25], [@CR26]\]. Nevertheless, patients included in this study who were deemed fit enough to tolerate iC were likely to be better performers, and the lack of this information is a confounder on our interpretation. Moreover, the receipt of more aggressive therapy (such as iC and dose escalated RT) would presumably improve outcomes. As part of our methodology, we excluded patients who survived less than 3 months after their diagnosis in order to omit patients who would have been unlikely to complete their course of treatment. Of note, no patients who were excluded for survival less than 3 months, received dose-escalated RT. While this may have unintentionally excluded patients who had increased toxicities from their treatment course, our suspicion that this small number of excluded patients would have suffered acute or fatal toxicities from dose escalation was relatively low, based on several studies \[[@CR6], [@CR7]\].

Dose-escalated RT is limited by normal tissue dose constraints, which can result in significant acute and late toxicities. Specifically, tumors in close proximity to stomach and duodenum may limit the amount of RT that could be safely delivered, due to concerns for radiation-induced gastrointestinal toxicities. In this study, no treatment interaction was seen in patients with a tumor size or with tumors located at the body or tail of the pancreas. These variables were also statistically insignificant for survival outcomes after Cox MVA in our study, indicating that they less likely play a major role in the survival outcome of dose escalation seen in both cohorts. Specific toxicities in the two cohorts could not be assessed in this study, since this data is not collected by the NCDB.

The database was also re-examined to evaluate 848 patients who had CA 19--9 factor values, ranging from 0 to \> 98. Among 398 patients with no iC, only 47 patients received escalated dose-escalated RT. The sample size of the cohorts with escalated radiation dose was felt to be too small for repeating propensity scored matching. Among 450 patients with induction chemotherapy, only 92 patients received dose-escalated RT. With 1:1 propensity score matching of baseline characteristics including CA 19--9 values, a total of 174 patients were matched. Other ratios such as 2:1 could not be performed since not all patients (55+ Gy) were matched with corresponding, control patients (45--55 Gy). Patients with dose-escalated RT were associated with improved overall survival (log-rank *p* = 0.013).

Conclusion {#Sec10}
==========

This novel NCDB analysis of patients with unresectable, cT4 N0--1 pancreatic cancer shows that dose-escalated RT with concurrent chemotherapy improves survival in patients who have received iC. Use of dose-escalated RT in this setting may be the favored option for definitive treatment of unresectable pancreatic cancer, and further studies may be warranted for this challenging patient population.
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